國家衛生研究院 NHRI:Item 3990099045/10639
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 857710      在线人数 : 762
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/10639


    题名: Multicenter study of clinical features of breakthrough acinetobacter bacteremia during carbapenem therapy
    作者: Lee, YT;Wang, YC;Kuo, SC;Chen, CT;Liu, CP;Liu, YM;Chen, TL;Yang, YS
    贡献者: Division of Infectious Diseases
    摘要: Breakthrough Acinetobacter bacteremia during carbapenem therapy is not uncommon and creates therapeutic dilemmas for clinicians. This study was conducted to evaluate the clinical and microbiological characteristics of breakthrough Acinetobacter bacteremia during carbapenem therapy and to assess the efficacy of various antimicrobial therapies. We analyzed 100 adults who developed breakthrough Acinetobacter bacteremia during carbapenem therapy at 4 medical centers over a 6-year period. Their 30-day mortality rate was 57.0% and the carbapenem resistance rate of their isolates was 87.0%. Among patients with carbapenem-resistant Acinetobacter bacteremia, breakthrough bacteremia during carbapenem therapy was associated with a significant higher 14-day mortality (51.7% versus 37.4%, P = 0.025 by bivariate analysis) and a higher 30-day mortality (P = 0.037 by log-rank test of survival analysis) than in the non-breakthrough group. For treatment of breakthrough Acinetobacter bacteremia during carbapenem therapy, tigecycline-based therapy was associated with a significantly higher 30-day mortality (80.0%) than continued carbapenem therapy (52.5%) and colistin-based therapy (57.9%) by survival analysis (P = 0.047 and 0.045 by log-rank test, respectively). Cox regression controlling for confounders, including severity of illness indices, demonstrated that patients treated with tigecycline-based therapy for breakthrough Acinetobacter bacteremia was an independent predictor of 30-day mortality (hazard ratio, 3.659; 95% confidence interval, 1.794-7.465; P < 0.001). Patients with breakthrough Acinetobacter bacteremia during carbapenem therapy posed a poor outcome. Tigecycline should be used cautiously for treatment of breakthrough Acinetobacter bacteremia that develops during carbapenem therapy.
    日期: 2017-09
    關聯: Antimicrobial Agents and Chemotherapy. 2017 Aug;61(9):Article number e00931-17.
    Link to: http://dx.doi.org/10.1128/aac.00931-17
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0066-4804&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000408309000063
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85028311922
    显示于类别:[郭書辰] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    PUB28674056.pdf344KbAdobe PDF325检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈